+86-28-82633987sales@biopurify.com
cnen
  • iso9001 iso9001
  • iso17025 iso17025
  • usp usp
Alternate Text
Home > Product Catalog > Botanical Source

Picfeltarraenin IA

CAS No.:97230-47-2

Picfeltarraenin IA
Catalogue No.: BP1095
Formula: C41H62O13
Mol Weight: 762.934
Contacts
+86-28-82633860  +86-18080483897
skype skype
Email: sales@biopurify.com biopurify@gmail.com

Picfeltarraenin IA

CAS No.:97230-47-2

Picfeltarraenin IA
Catalogue No.: BP1095
Formula: C41H62O13
Mol Weight: 762.934
Contacts
+86-28-82633860  +86-18080483897
skype skype
Email: sales@biopurify.com biopurify@gmail.com
Over 15 years of industry experience in phytochemicals from R&D(reference substances) to Industrialization, please feel free to contact us!

Synonym name:
Catalogue No.: BP1095
Cas No.: 97230-47-2
Formula: C41H62O13
Mol Weight: 762.934
Botanical Source: Picria fel-tarrae

Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle
Can be supplied from milligrams to grams.

For Reference Standard and R&D, Not for Human Use Directly.
Inquire for bulk scale.

 

 

Description:

Picfeltarraenin IA has anti-inflammatory activity, it is a strong AChE inhibitior, and an potential PI3K and epidermal growth factor receptor (EGFR ) inhibitor. It acts as an inhibitor on both the classical and alternative pathways of the complement system.

 

References:

Oncol Lett. 2016 Feb;11(2):1195-1200.    

Picfeltarraenin IA inhibits lipopolysaccharide-induced inflammatory cytokine production by the nuclear factor-κB pathway in human pulmonary epithelial A549 cells.    

The present study aimed to investigate the effect of Picfeltarraenin IA (IA) on respiratory inflammation by analyzing its effect on interleukin (IL)-8 and prostaglandin E2 (PGE2) production. The expression of cyclooxygenase 2 (COX2) in human pulmonary adenocarcinoma epithelial A549 cells in culture was also examined. 

METHODS AND RESULTS:

Human pulmonary epithelial A549 cells and the human monocytic leukemia THP-1 cell line were used in the current study. Cell viability was measured using a methylthiazol tetrazolium assay. The production of IL-8 and PGE2 was investigated using an enzyme-linked immunosorbent assay. The expression of COX2 and nuclear factor-κB (NF-κB)-p65 was examined using western blot analysis. Treatment with lipopolysaccharide (LPS; 10 μg/ml) resulted in the increased production of IL-8 and PGE2, and the increased expression of COX2 in the A549 cells. Furthermore, IA (0.1-10 μmol/l) significantly inhibited PGE2 production and COX2 expression in cells with LPS-induced IL-8, in a concentration-dependent manner. The results suggested that IA downregulates LPS-induced COX2 expression, and inhibits IL-8 and PGE2 production in pulmonary epithelial cells. Additionally, IA was observed to suppress the expression of COX2 in THP-1 cells, and also to regulate the expression of COX2 via the NF-κB pathway in the A549 cells, but not in the THP-1 cells. 

CONCLUSIONS:

These results indicate that IA regulates LPS-induced cytokine release in A549 cells via the NF-κB pathway.    

Related Products